Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review

Endocrine therapy (ET), associated with CDK 4/6 inhibitors, represents the first choice of treatment for HR+/HER2- metastatic breast cancer (mBC). Primary or secondary endocrine resistance could develop; however validated biomarkers capable of predicting such a conditions are not available. Several...

Descripción completa

Detalles Bibliográficos
Autores principales: Canino, Fabio, Piacentini, Federico, Omarini, Claudia, Toss, Angela, Barbolini, Monica, Vici, Patrizia, Dominici, Massimo, Moscetti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266387/
https://www.ncbi.nlm.nih.gov/pubmed/35806079
http://dx.doi.org/10.3390/ijms23137079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266387/
https://www.ncbi.nlm.nih.gov/pubmed/35806079
http://dx.doi.org/10.3390/ijms23137079

Ejemplares similares